The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 2.4% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading oversold. Over the past year the shares are up 27%. Our forward projection puts the odds of a 10% gain over the next month near 16%.
Sabine Royalty Trust
SBR · the NYSE · USD · Market cap $944M
PASS · Titan EthicalPrice as of 19 Nov 2026Daily close, not a live quote
Screened 2026-11-19 · the tape above runs as of 08:05 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price61.49 USD at the 19 Nov 2026 close
- Fair valueUnder review: our model has no usable estimate for it yet.
- Our regime readMarkdown, as of 16 Nov 2026
- Ethical screenPasses
- Last reviewed19 Nov 2026 (1 day ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
Our fair-value range: range not available (screen dated 2026-11-19).
- Trend Markdown
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options no verdict drawn today, left as found
- Ethical passes the values gate
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its markdown label.
Sabine Royalty Trust holds its Markdown at $61.49. Consolidating, no directional conviction, held for 220 days.
| Phase | Markdown · caution |
| Quantitative state | Consolidating, no directional conviction, held for 220 days |
| Price at the screen | $61.49 |
| Valuation | 13.21 trailing · N/A forward price to earnings |
| Values screen | PASS |
| Beta | 0.30 |
Five Screens: SBR's Results
PASS. All five recorded results clear their limits.
| Test | Figure | Limit | Status |
|---|---|---|---|
| Business activity | Permissible | Permissible core business | Pass |
| Debt load | 0.00% | Below 33% | Pass |
| Interest-bearing cash | 0.67% | Below 33% | Pass |
| Receivables | 0.00% | Below 49% | Pass |
| Revenue purity | 0.61% | Below 5% | Pass |
Definitions, sources and threshold rules: ticker values-screen methodology.
The Ethical ReadWhy It Clears, in Plain English
Sabine Royalty Trust clears all five screens. Its business is in a permissible area, its debt is near-nil, and almost none of its income is interest, so it passes.
Read as at 2026-11-19. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when SBR's ethical verdict changes
Today SBR passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The Fair Value Range
Fair value under review. Our model has no usable estimate for it yet. We show no fair value, margin of safety or value read built on it until the review clears.
Model construction and limits: fair-value methodology.
Price History & ProjectionsWhere our models see it going: no fair-value estimate yet, range not available, dated to the 2026-11-19 screen.
How our estimate and third-party targets differ.
The Business, in Plain Words| Trailing P/E | 13.2xreasonably valued |
| EPS, trailing | 4.90 |
| Revenue growth | +16.5%steady growth |
| Profit margin | 94.7%highly profitable on every dollar of sales |
| Return on equity | 914.2%an exceptional return on shareholder capital |
| Dividend yield | 7.05% |
| Current ratio | 31.55comfortably covers its short-term bills |
| Beta | 0.30barely tracks the market's swings |
| Short interest, float | 0.00% |
| 52-week range | 64.65 - 79.86 |
| Market cap | $944M |
SBR-specific watchpoints · The things to watch: it's a small-cap, so the share price can swing harder than the market.
Metric definitions and interpretation rules: ticker-page methodology.
Every Entry, As Written
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 2.6% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 0% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 27%. Our forward projection puts the odds of a 10% gain over the next month near 16%. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 1.5% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 0% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 27%. Our forward projection puts the odds of a 10% gain over the next month near 16%. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.9% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 0% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 27%. Our forward projection puts the odds of a 10% gain over the next month near 16%. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 2.2% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 0% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 27%. Our forward projection puts the odds of a 10% gain over the next month near 16%. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 0% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 27%. Our forward projection puts the odds of a 10% gain over the next month near 16%. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 0% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 27%. Our forward projection puts the odds of a 10% gain over the next month near 16%. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.6% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 0% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 27%. Our forward projection puts the odds of a 10% gain over the next month near 16%. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.9% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 0% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 27%. Our forward projection puts the odds of a 10% gain over the next month near 16%. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.7% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 0% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 27%. Our forward projection puts the odds of a 10% gain over the next month near 16%.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
- Sabine Royalty: Q3 Earnings Snapshot Yahoo Finance · 14d ago
- SABINE ROYALTY TRUST ANNOUNCES MONTHLY CASH DISTRIBUTION FOR NOVEMBER 2026 Yahoo Finance · 14d ago
- The Bull Case For Sabine Royalty Trust (SBR) Could Change Following Higher Payout And Oil-Heavy Mix Yahoo Finance · 9 Oct 2026
- SABINE ROYALTY TRUST ANNOUNCES MONTHLY CASH DISTRIBUTION FOR OCTOBER 2026 Yahoo Finance · 5 Oct 2026
- SABINE ROYALTY TRUST ANNOUNCES MONTHLY CASH DISTRIBUTION FOR SEPTEMBER 2026 Yahoo Finance · 4 Sep 2026
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
Screened names in the same industry · explore each on its own page.
| Date | Politician | Party | Type | Amount |
|---|---|---|---|---|
| 2026-07-24 | John Fetterman | Democrat | sell | 1K–15K |
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $71.90 | -14.7% | $0.36 | $859 | -14.1% |
| 2 months | $72.71 | -15.6% | $0.72 | $854 | -14.6% |
| 3 months | $71.58 | -14.3% | $1.05 | $872 | -12.8% |
| 6 months | $74.31 | -17.4% | $2.60 | $861 | -13.9% |
| 1 year | $73.50 | -16.5% | $4.51 | $896 | -10.4% |
| 2 years | $54.03 | +13.6% | $9.79 | $1,317 | +31.7% |
| 3 years | $48.53 | +26.4% | $16.07 | $1,595 | +59.5% |
| 5 years | $27.18 | +125.8% | $30.28 | $3,372 | +237.2% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever SBR does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.